MedTrace Logo

Acute Excposure of High Altitude on ECG and Non-invasive Blood Pressure.

NCT03593083 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-01-07

No results posted yet for this study

Summary

Randomized crossover trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response of High Altitude (Säntis, 2500m above sea level) on ECG repolarizations and non-invasive blood pressure measurements by Finapres® NOVA Technology.

Conditions

  • Pulmonary Hypertension

Interventions

OTHER

Low altitude: 470m above sea level

Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

OTHER

Säntis; 2500m above sea Level

Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Silvia Ulrich, Prof. · University of Zurich

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2019-01-01
Completion
2019-01-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03593083 on ClinicalTrials.gov